Search
Gevokizumab
go.drugbank.com/drugs/DB12119InvestigationalGevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.
Sulfacytine
go.drugbank.com/drugs/DB01298ApprovedSulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle.
TRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigationalisolated from an HLA-matched donor's mobilized peripheral blood — purified hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcons) — administered as
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigationalPalopegteriparatide is a parathyroid hormone (PTH) analog. Palopegteriparatide is a prodrug consisting of PTH(1-34) conjugated to a methoxy polyethylene glycol carrier (mPEG) via a proprietary TransCon Linker. PTH(1-34) contains the N-te...
Azithromycin
go.drugbank.com/drugs/DB00207ApprovedInvestigationalAzithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 . It is primarily used for the treatment of respiratory, enteric and genit...
Products: AZITROMICINA MYLAN GENERICS, AZITROMICINA DOC GENERICIATG002
go.drugbank.com/drugs/DB05068InvestigationalATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process.
ND1251
go.drugbank.com/drugs/DB05132ExperimentalND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and certain respiratory diseases.
Anti-SARS-CoV-2 equine immunoglobulin fragments
go.drugbank.com/drugs/DB16368InvestigationalAnti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine